Helus Pharma builds on the strong foundation originally created as Cybin Inc., reflecting the Company’s ongoing transformation to a commercial stage pharmaceutical company Helus Pharma...
Cybin Inc. (NYSE American:CYBN) (Cboe Canada CA:CYBN) (“ Cybin ” or the “ Company ”), a clinical-stage breakthrough neuropsychiatry company committed to advancing mental...
Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN), a clinical-stage breakthrough pharmaceutical company committed to revolutionizing mental healthcare by developing innovative next-generation treatment options,...
Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) , a clinical-stage breakthrough pharmaceutical company committed to revolutionizing mental healthcare by developing innovative next-generation treatment options,...
- Closed registered direct offering for aggregate gross proceeds of US$175 million (the “Registered Direct Offering”) led by a syndicate of prominent biopharmaceutical institutional investors - ...
Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (”Cybin” or the “Company”), a breakthrough Phase 3 clinical stage neuropsychiatry company committed to revolutionizing mental healthcare through...
- Company to host conference call and webcast at 8:00 a.m. ET on Thursday, November 13, 2025 -
Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (”Cybin” or the “Company”), a breakthrough Phase 3 clinical stage neuropsychiatry company committed to revolutionizing mental healthcare through...
- Chief Medical Officer Amir Inamdar to participate in a panel on November 5, 2025 -
Cybin Inc. (Cboe CA: CYBN) (NYSE American: CYBN) (“ Cybin ” or the “ Company ”), a breakthrough Phase 3 clinical stage neuropsychiatry company committed to revolutionizing...